Engineered bacterial extracellular vesicles for central nervous system diseases

J Control Release. 2023 Dec:364:46-60. doi: 10.1016/j.jconrel.2023.10.027. Epub 2023 Oct 25.

Abstract

The prevalence of central nervous system (CNS) diseases is on the rise as the population ages. The presence of various obstacles, particularly the blood-brain barrier (BBB), poses a challenge for drug delivery to the CNS. An expanding body of study suggests that gut microbiota (GM) plays an important role in CNS diseases. The communication between GM and CNS diseases has received increasing attention. Accumulating evidence indicates that the GM can modulate host signaling pathways to regulate distant organ functions by delivering bioactive substances to host cells via bacterial extracellular vesicles (BEVs). BEVs have emerged as a promising platform for the treatment of CNS diseases due to their nanostructure, ability to penetrate the BBB, as well as their low toxicity, high biocompatibility, ease of modification and large-scale culture. Here, we discuss the biogenesis, internalization mechanism and engineering modification methods of BEVs. We then focus on the use and potential role of BEVs in the treatment of CNS diseases. Finally, we outline the main challenges and future prospects for the application of BEVs in CNS diseases. We hope that the comprehensive understanding of the BEVs-based gut-brain axis will provide new insights into the treatment of CNS diseases.

Keywords: Bacterial extracellular vesicles; Central nervous system diseases; Gut-brain axis; Synthetic biology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Transport
  • Blood-Brain Barrier / metabolism
  • Central Nervous System Diseases* / metabolism
  • Central Nervous System Diseases* / therapy
  • Extracellular Vesicles* / metabolism
  • Humans
  • Signal Transduction